PMID- 29772037
OWN - NLM
STAT- MEDLINE
DCOM- 20181003
LR  - 20190101
IS  - 1201-5989 (Print)
IS  - 1201-5989 (Linking)
VI  - 23
IP  - 3
DP  - 2018 May
TI  - Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology.
PG  - 5-9
AB  - The class of medications known as Janus kinase inhibitors block cytokine-mediated 
      signaling via the Janus kinase-signal transducer and activator of transcription 
      (JAK-STAT) pathway, which plays an important role in immunoregulation and normal 
      cell growth. This class includes the drugs tofacitinib, approved for the 
      treatment of rheumatoid arthritis, and ruxolitinib, approved for the treatment of 
      myelofibrosis and polycythemia rubra vera. The most common adverse events (AEs) 
      reported in patients taking tofacitinib are infections, whereas the most common 
      AEs in patients taking ruxolitinib are anemia and thrombocytopenia. Both first 
      and second generation Janus kinase inhibitors have become promising treatment 
      modalities for dermatologic conditions such as psoriasis, atopic dermatitis, 
      alopecia areata, vilitigo, dermatomyositis, and graft-versus-host disease. Future 
      promising areas of investigation include treatment of cutaneous lupus, cutaneous 
      T-cell lymphoma, melanoma, allergic contact dermatitis, and lichen planus.
FAU - Cinats, A
AU  - Cinats A
AD  - Division of Dermatology, University of Calgary, Calgary, AB, Canada.
FAU - Heck, E
AU  - Heck E
AD  - Queen's University School of Medicine, Queen's University, Kingston, ON, Canada.
FAU - Robertson, L
AU  - Robertson L
AD  - Division of Dermatology, University of Calgary, Calgary, AB, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Canada
TA  - Skin Therapy Lett
JT  - Skin therapy letter
JID - 9891441
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Dermatologic Agents)
RN  - 0 (Janus Kinase Inhibitors)
RN  - EC 2.7.10.2 (Janus Kinases)
SB  - IM
MH  - Anti-Inflammatory Agents/adverse effects/*therapeutic use
MH  - Dermatologic Agents/adverse effects/*therapeutic use
MH  - Dermatology
MH  - Humans
MH  - Janus Kinase Inhibitors/adverse effects/*therapeutic use
MH  - Janus Kinases/*antagonists & inhibitors
MH  - Skin Diseases/*drug therapy/enzymology
OTO - NOTNLM
OT  - Janus kinase inhibitors
OT  - JAK inhibitors
OT  - JAK-STAT pathway
OT  - tofacitinib
OT  - ruxolitinib
OT  - alopecia areata
OT  - atopic dermatitis
OT  - dermatomyositis
OT  - graft-versus-host disease
OT  - psoriasis
OT  - vitiligo
EDAT- 2018/05/18 06:00
MHDA- 2018/10/04 06:00
CRDT- 2018/05/18 06:00
PHST- 2018/05/18 06:00 [entrez]
PHST- 2018/05/18 06:00 [pubmed]
PHST- 2018/10/04 06:00 [medline]
AID - Janus kinase inhibitors, JAK inhibitors, JAK-STAT pathway, tofacitinib, 
      ruxolitinib, alopecia areata, atopic dermatitis, dermatomyositis, 
      graft-versus-host disease, psoriasis, vilitigo [pii]
PST - ppublish
SO  - Skin Therapy Lett. 2018 May;23(3):5-9.